The estimated Net Worth of Geraldine Henwood is at least $6.57 Миллион dollars as of 15 December 2022. Ms. Henwood owns over 1,200 units of Recro Pharma Inc stock worth over $5,072 and over the last 13 years she sold REPH stock worth over $1,944,925. In addition, she makes $4,622,980 as President, Chief Executive Officer и Director at Recro Pharma Inc.
Geraldine has made over 13 trades of the Recro Pharma Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently she bought 1,200 units of REPH stock worth $3,060 on 15 December 2022.
The largest trade she's ever made was selling 144,806 units of Recro Pharma Inc stock on 13 May 2019 worth over $1,287,325. On average, Geraldine trades about 8,270 units every 77 days since 2011. As of 15 December 2022 she still owns at least 2,427 units of Recro Pharma Inc stock.
You can see the complete history of Ms. Henwood stock trades at the bottom of the page.
Geraldine A. Henwood serves as President, Chief Executive Officer, Director of the Company. Ms. Henwood also serves as Chief Executive Officer and a director of Baudax. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, or MCG, a pharmaceutical incubator and consulting firm. From 1999 to 2006, Ms. Henwood was the President and Chief Executive Officer of Auxilium Pharmaceuticals, Inc., a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and Chief Executive Officer of IBAH, Inc., a contract research organization. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc. She rose through the ranks to be a Brand Manager, then the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director—Marketing in the International Pharmaceutical Division. Ms. Henwood currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, a position she has held since May 2015, and she previously served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015, and on the board of directors of MAP Pharmaceuticals, Inc., a biopharmaceuticals company, from 2004 until its acquisition by Allergan, Inc. in March 2013.
As the President, Chief Executive Officer и Director of Recro Pharma Inc, the total compensation of Geraldine Henwood at Recro Pharma Inc is $4,622,980. There are no executives at Recro Pharma Inc getting paid more.
Geraldine Henwood is 66, she's been the President, Chief Executive Officer и Director of Recro Pharma Inc since 2008. There are 3 older and 6 younger executives at Recro Pharma Inc. The oldest executive at Recro Pharma Inc is Winston Churchill, 79, who is the Independent Director.
Geraldine's mailing address filed with the SEC is C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN, PA, 19355.
Over the last 11 years, insiders at Recro Pharma Inc have traded over $25,533,136 worth of Recro Pharma Inc stock and bought 3,055,820 units worth $22,429,197 . The most active insiders traders include Healthcare Master Fund Ltd ..., Investment Company, Inc. Awm и James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of $151,953. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth $1,004.
Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
Recro Pharma Inc executives and other stock owners filed with the SEC include: